


Common  $\gamma$ -chain cytokines

IL-2, IL-4,  
IL-7, IL-9,  
IL-15 & IL-21




STAT 1  
STAT 3  
STAT 5  
STAT 6

Inflammation  
Cellular differentiation  
Lymphoid cell maturation

Common  $\beta$ -chain cytokines


IL-3, IL-5,  
TPO, G-CSF,  
GM-CSF, EPO  
GH & leptin



STAT 3  
STAT 5

Myelopoiesis  
Erythropoiesis  
Thrombopoiesis  
Growth  
Mammary development

IL-12, IL-23  
Type III IFN




STAT 3  
STAT 4

Innate immunity  
Inflammation  
Th17 cell differentiation & proliferation

IFN- $\alpha/\beta$  & IL-10 family


IFN- $\alpha$ ,  
IFN- $\beta$ ,  
IL-10, IL-20,  
IL-22, IL-28



STAT 1  
STAT 2  
STAT 3

Inflammation  
Anti-tumour  
Anti-viral

IFN- $\alpha$ ,  
IFN- $\beta$ , IFN- $\gamma$




STAT 1  
STAT 2  
STAT 3

Inflammation  
Anti-viral  
Anti-mycobacterial

gp130 cytokines


IL-6, IL-11,  
IL-13, IL-25,  
IL-27, IL-31  
OSM & LIF



STAT 1  
STAT 3  
STAT 6

Acute inflammation  
Lymphocyte growth differentiation & function  
Catabolic metabolism  
Lipid metabolism  
Bone resorption

IL-10, IL-19,  
IL-20, IL-22  
& IL-26



STAT 3

Anti-inflammatory  
Barrier immunity  
B cell activation  
Synoviocyte & osteoclast function

Schwartz DM et al. Nat Rev Drug Discov. 2017; 16: 843-862  
Salas A et al. Nat Rev Gastroenterol Hepatol. 2020; 17:323-337  
Gran AH et al. Front. Immunol. 2021; 13:12:690477  
Quintos-Cardama A et al. Nat Rev Drug Discov. 2011; 10(2):127-40

JAK1 preferential inhibition: Filgotinib and upadactinib

Non-selective inhibition: Tofacitinib

